Gclm — Glutamate Cysteine Ligase Modifier Subunit is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| GCLM — Glutamate-Cysteine Ligase Modifier Subunit | |
|---|---|
| Symbol | GCLM |
| Full Name | Glutamate-Cysteine Ligase Modifier Subunit |
| Chromosome | 1p22.1 |
| NCBI Gene | 2739 |
| Ensembl | ENSG00000100916 |
| OMIM | 606466 |
| UniProt | P48507 |
| Diseases | [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers-disease), Oxidative Stress |
| Expression | Liver, Kidney, Brain, Lung |
GCLM (Glutamate-Cysteine Ligase Modifier Subunit) is a gene located on chromosome 1p22.1 that encodes the modifier subunit of glutamate-cysteine ligase (GCL), the rate-limiting enzyme in glutathione biosynthesis. GCL catalyzes the first step in the synthesis of glutathione (GSH), a crucial antioxidant that protects cells from oxidative damage. The enzyme consists of a catalytic subunit (GCLC) and a modifier subunit (GCLM), which together regulate cellular glutathione levels.
GCLM forms a heterodimer with GCLC (glutamate-cysteine ligase catalytic subunit) to create functional glutamate-cysteine ligase. The modifier subunit lowers the Km for glutamate and increases the Kcat (turnover rate) of the enzyme, enhancing the overall efficiency of glutathione synthesis[1].
Glutathione (GSH) is the most abundant intracellular thiol and serves as:
GCLM expression is primarily regulated through the Nrf2 (Nuclear factor erythroid 2-related factor 2) pathway:
GCLM is strongly implicated in Parkinson's disease pathogenesis:
GCLM polymorphisms contribute to AD risk and progression:
GCLM variants modify disease phenotype in some familial ALS cases:
GCLM expression changes affect HD pathogenesis:
GCLM plays a protective role in cerebrovascular injury:
The Nrf2-GCLM axis is a central neuroprotective pathway[6:1]:
GCLM dysfunction intersects with multiple neurodegeneration mechanisms:
| Compound | Mechanism | Status |
|---|---|---|
| Sulforaphane | Covalent Keap1 modification | Preclinical, strong neuroprotection in PD models |
| Bardoxolone methyl | Nrf2 activation, anti-inflammatory | Phase 2 for diabetic nephropathy |
| Dimethyl fumarate | Nrf2 activation, immunomodulatory | FDA-approved for MS |
| Curcumin | Nrf2 activation, antioxidant | Limited by bioavailability |
| Approach | Compound | Rationale |
|---|---|---|
| Direct GSH precursors | N-acetylcysteine (NAC) | Provides cysteine, increases GSH |
| GSH analogs | GSH ethyl ester | Better brain penetration |
| GCLM expression | Gene therapy (AAV-Nrf2) | Upregulate Nrf2-GCLM axis |
GCLM promoter polymorphisms (rs41303970, rs41303971) affect:
Koike K, et al. Involvement of Nrf2 activation in the upregulation of GCLM by pyrrolidine dithiocarbamate. Redox Rep. 2005. ↩︎
Gu F, et al. GCLM polymorphisms and risk of Parkinson's disease in Chinese population. Neurosci Lett. 2007. ↩︎ ↩︎
Naylor JK, et al. Genetic variation in the glutamate cysteine ligase modifier gene and Alzheimer's disease risk. J Neural Transm. 2008. ↩︎ ↩︎
Wilson MR, et al. Glutathione deficits in Alzheimer's disease and Parkinson's disease brains. Brain Res. 2014. ↩︎ ↩︎
Shih AY, et al. Coordinate regulation of glutathione synthesis and release by Nrf2-expressing glia. J Neurosci. 2000. ↩︎
Embury CM, et al. Nrf2 activation by sulforaphane restores GCLM and provides neuroprotection in models of Parkinson's disease. Neuropharmacology. 2019. ↩︎ ↩︎
Chen XY, et al. GCLM rs41303970 polymorphism and susceptibility to neurodegenerative diseases. Oncotarget. 2017. ↩︎ ↩︎ ↩︎
Mercier CM, et al. Glutamate cysteine ligase modifier deficiency and Parkinson's disease. Neurobiol Aging. 2013. ↩︎
Johann S, et al. Genetic polymorphisms of glutamate cysteine ligase modifier and Parkinson's disease risk. J Neurol Sci. 2017. ↩︎
Yang Y, et al. GCLM promoter variants and their effect on susceptibility to Parkinson's disease. Free Radic Biol Med. 2010. ↩︎
Chen L, et al. Targeting Nrf2-GCLM pathway for neuroprotection in Alzheimer's disease. Antioxid Redox Signal. 2019. ↩︎ ↩︎
Osborne NN, et al. Glutathione metabolism in retinal disease and neuroprotection. Prog Retin Eye Res. 2022. ↩︎ ↩︎